Shukra Pharmaceuticals (524632) Q3 25/26 earnings summary

Executive summary

• Board approved unaudited financial results for Q3 and nine months ended December 31, 2025, and re-appointed the Managing Director for a five-year term.

• Statutory auditors provided an unqualified review opinion on both standalone and consolidated results.

Financial highlights

• Q3 FY26 consolidated revenue from operations was ₹3,913.48 lakhs, up from ₹1,058.43 lakhs in Q3 FY25.

• Net profit for Q3 FY26 stood at ₹2,036.46 lakhs, compared to ₹316.44 lakhs in Q3 FY25.

• For the nine months ended December 31, 2025, total income was ₹5,404.09 lakhs and net profit was ₹2,377.46 lakhs.

• Basic and diluted EPS for Q3 FY26 was ₹0.47, up from ₹0.72 in Q3 FY25.

Outlook and guidance

• Board reviewed ongoing business and confirmed continued focus on operational excellence and growth.